Gilead Sciences traded at $129.33 this Friday July 24th, decreasing $1.53 or 1.17 percent since the previous trading session. Looking back, over the last four weeks, Gilead Sciences lost 4.43 percent. Over the last 12 months, its price rose by 11.30 percent. Looking ahead, we forecast Gilead Sciences to be priced at 126.60 by the end of this quarter and at 118.76 in one year, according to Trading Economics global macro models projections and analysts expectations.
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.